A Bank of Canada staff paper found that Aave V3 reported zero non-performing loans in 2024, with overcollateralization and ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His had a long list, unfortunately closed by his passing away at the age of 92 ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Soroosh Khodami discusses why we aren't ready ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...